Cytori Therapeutics, Inc. (NASDAQ: CYTX) will release financial results
for the quarter ended June 30, 2008 on Friday, Aug 8th at approximately
7:00 a.m. Eastern Daylight Time (EDT). The company will host a
conference call with management at 10:30 a.m. EDT to discuss the results
and provide an update on the business.
The audio webcast of the conference call may be accessed under “Events
& Webcasts” in the Investor Relations
section of the Company’s website at www.cytoritx.com.
The webcast will be available live and by replay two hours after the
call on the company’s website and archived for
90 days. A telephone replay will be available for one week. To access
the replay, please call +1 (303) 590-3000 (PIN: 11116771#).
About Cytori
Cytori’s (NASDAQ: CYTX) goal is to be the
global leader in regenerative medicine. The company is dedicated to
providing patients with new options for reconstructive surgery,
developing treatments for cardiovascular disease, and banking patients'
adult stem and regenerative cells. The Celution®
800 System is being introduced in Europe into the reconstructive surgery
market while the Celution® 900
System is being commercialized globally for cryopreserving a patient's
own stem and regenerative cells. Clinical trials are ongoing in
cardiovascular disease and planned for spinal disc degeneration,
gastrointestinal disorders, and other unmet medical needs. www.cytoritx.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating
results and financial position. Such statements are subject to risks and
uncertainties that could cause our actual results and financial position
to differ materially. Some of these risks and uncertainties include, but
are not limited to, statements regarding (a) securing sufficient
operating capital, (b) the need for further financing, (c) our history
of operating losses, (d) our anticipated revenue growth from StemSource
Cell Bank orders, (e) our revenue guidance for 2008, (f) protection of
our intellectual property rights, (g) our collaboration with the
Fraunhofer Society and the related clinical trials, and other risks and
uncertainties described under the "Risk Factors" in Cytori’s
Securities and Exchange Commission Filings. We assume no responsibility
to update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made.
Cytori Therapeutics
Tom Baker, 858-875-5258
tbaker@cytoritx.com
